A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

Also called NCT07776509

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 500 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07776509
  • EU CT 2025-523295-23-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Brazil, Canada, China, Denmark, Israel, Japan, Sweden, Türkiye, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07776509. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-24 (actual); primary completion 2028-08-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
Acronym
SELENE 3
Condition
Obesity or Overweight
Condition
Weight-Related Comorbidity
Condition
With/Without Diabetes Mellitus, Type 2
Intervention (Drug)
Lenbelintide
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07776509
Content hash
0e4ea31d1532f8d8476b8b827e97b92159e759a238547a50cabc9aa6d1ddc399